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Abstract
Background: In patients treated with transcatheter aortic valve implantation (TAVI), age is recognized 
as one of the most important risk factors. The aim of our study was to evaluate whether early and mid-
term results of TAVI were worse in patients over 85 year old compared with the younger population.
Methods: From September 2010 to November 2015, 162 consecutive patients (mean age 78.4 ± 7.1 years,  
47.5% females) underwent TAVI in our Institution. Patients were divided into two groups: 1) elderly 
(≥ 85 year old) and 2) younger patients (< 85 year old). Primary clinical study endpoints were the fol-
lowing: death, myocardial infarction, stroke, major and minor access site, and bleeding complications. 
The secondary endpoints included: pacemaker implantation rate, paravalvular leakage, acute kidney 
injury, and duration of hospitalization.
Results: Twenty-six patients were 85 or older (mean 87.5 ± 2.1). In the remaining 136 (84%), the 
average age was 76.7 ± 6.4. Baseline clinical profiles were similar in both groups, though history of pre-
vious cardiac surgery (p = 0.0047) and chronic obstructive pulmonary disease (p = 0.0099) were more 
common in the younger group, and glomerular filtration rate was lower in the older group (p = 0.045). 
Major, life threatening and minor bleeding complications, as well as vascular access site complications 
did not differ between the two groups. Rates of myocardial infarction and stroke were comparably low 
in both groups. Similar results were also found in the incidence of secondary endpoints. In-hospital 
mortality and 1-year mortality did not differ between groups.
Conclusions: TAVI in patients aged 85 and older is still a relatively safe procedure and age itself 
should not be a discriminatory factor in TAVI qualification. (Cardiol J 2017; 24, 4: 358–363)
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Introduction
Transcatheter aortic valve implantation (TAVI) 
has currently become an established method of 
treatment of patients with severe aortic stenosis 
who are inoperable or with very high surgical 
risk. Among risk factors, age is one of the most 
important taken into account in patients’ risk 
assessment, including EuroScore and Society of 
Thoracic Surgeons (STS) score.
There are still doubts whether age itself 
is the strongest predictor of survival in TAVI 
patients.
Therefore, we have decided to compare peri- 
and post-procedural outcomes in patients who were 
85 years old or older to the younger ones.
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Methods
From September 2010 to November 2015, 162 
consecutive patients (mean age 78.4 ± 7.1 years, 
47.5% females) underwent TAVI in our Institution 
with the implantation of CoreValve (n = 109), Core-
Valve Evolut (n = 27), Lotus (n = 16) or Symetis 
(n = 8). Patients were divided into two groups: 
1) elderly (≥ 85 year old) and 2) younger patients 
(< 85 year old). The demographic, clinical, and 
peri-procedural data were analyzed.
The diagnosis of severe aortic stenosis was 
made on routine clinical and echocardiographic 
criteria. Patients were eligible for TAVI on the 
basis of the institutional heart team’s decision 
(general cardiologist, interventional cardiologist, 
echocardiographer and cardiac surgeon). The 
pre-procedural evaluation included coronary an-
giography, transthoracic echocardiography (TTE) 
and transesophageal echocardiography (TEE), 
contrast-enhanced computed tomography with off-
line reconstructions to evaluate the aorta, femoral 
and iliac arteries.
All procedures were performed by the same 
team of cardiologists, cardiac surgeons, and anes-
thesiologists in a hybrid operating room.
The procedures were performed under general 
anesthesia (n = 142, 87.7%) or deep sedation 
(n = 20, 12.3%). TEE monitoring was used based 
on the operator’s decision (56% of cases). In each 
patient, a temporary pacemaker was inserted from 
jugular or femoral vein for rapid pacing and as 
a prevention of potential consequences of atrio-
ventricular block.
In patients with percutaneous femoral ap-
proach, Prostar™ system or two Proglides™ were 
introduced before insertion of vascular sheath. Aor-
tic valve predilatation was performed in 108 patients 
with an undersized Z-MED II-X® balloon (NuMED 
Inc., USA). Once the prosthesis was correctly posi-
tioned, expanded, and deployed, contrast injection 
was performed to assess the presence and degree of 
paravalvular leak (PVL). Control angiography of the 
access site was performed to assess vessel patency 
and possible bleeding. For transapical access, left 
anterolateral minithoracotomy was performed in 
the 5th or 6th intercostal space. Pericardiotomy was 
performed and two 3-0 Prolene purse string sutures 
reinforced with Teflon pledgets were placed at the 
apex. The apex was punctured and soft guide wire 
was introduced across stenotic valve under fluoro-
scopic control. Then a 14 F sheath was introduced 
into the left ventricular apex to maintain intraven-
tricular access. Balloon valvuloplasty was performed 
during rapid ventricular pacing. The prosthesis was 
delivered through the introducer sheath, positioned 
across the aortic annulus, and deployed. The deliv-
ery system was removed and the apical purse-string 
sutures were tied. An 18 F chest tube was inserted 
to drain the left pleural cavity and the routine chest 
wall closure was performed.
After the procedure, patients were monitored 
for heart rhythm and basic life parameters. One day 
after an uncomplicated procedure, rehabilitation 
was started.
Antiplatelet therapy consisted of aspirin 75 mg 
daily life-long, and in patients with a recent his-
tory of coronary angioplasty or acute coronary 
syndrome, clopidogrel 75 mg per day was added, 
according to current guidelines [1]. In patients 
with atrial fibrillation, oral anticoagulants (OACs 
and NOACs) were stopped before the procedure 
and resumed on the second day after procedure.
Primary clinical study endpoints were the fol-
lowing: death, myocardial infarction (MI), stroke, 
major and minor access site, and bleeding compli-
cations. The secondary endpoints included: the 
incidence of pacemaker implantation, PVL, acute 
kidney injury (AKI), and duration of hospitalization 
defined in concordance with the Valve Academic 
Research Consortium-2 (VARC-2) definitions [2]. 
The study was approved by our institutional com-
mittee and respected the principles outlined in the 
Declaration of Helsinki.
Follow-up
All patients underwent follow-up visits includ-
ing overall medical evaluation, TTE, lab tests and 
electrocardiogram at 1-month, 6-months, 1 year, 
and then annually. In rare cases, where hospital 
visits were not possible, telephone contact was 
obtained.
Statistical analysis
Continuous variables were reported as mean 
and standard deviation and compared using the 
unpaired t test or nonparametric Mann-Whitney 
test. Categorical variables were reported as counts 
or percentages and compared by the Fisher’s exact 
test. All tests were 2-sided. P values less than 0.05 
were considered statistically significant. Statistical 
analysis was performed using GraphPad InStat 3 
(GraphPad Software, Inc. USA).
Results
Twenty-six (16%) patients were 85 or older 
(mean 87.5 ± 2.1, range 85–92 years). In the 
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remaining 136 (84%) patients, the average age was 
76.7 ± 6.4 (range 57–84 years). Baseline charac-
teristics of both groups are presented in Table 1. 
The estimated mean risk scores for the entire 
population were as follows: logistic EuroScore 
19.3 ± 14.2%, EuroScore II 7.11 ± 7.1%, and STS 
mortality risk score 13.9 ± 11.5. Both groups did 
not differ in terms of peri-operative risk scores, 
including logistic EuroScore (p = 0.3), EuroScore II 
(p = 0.9), and STS mortality risk (p = 0.4). Women 
comprised 53.9% of the elderly group and 46.3% of 
the younger group (p = 0.5). Baseline clinical pro-
files were quite similar, though history of previous 
cardiac surgery, including coronary artery bypass 
grafting (p = 0.0047) and chronic obstructive pul-
monary disease (COPD) (p = 0.0099), were more 
common in younger group, whereas glomerular 
filtration rate was lower in the older group (p = 0.045). 
Pre-procedural echocardiographic findings were 
similar in both groups. Patients with transapical 
procedures did not present significantly higher 
risk scores than the rest of the study group: logis-
tic EuroScore (16.7 ± 9 vs. 19.5 ± 14.5, p = 0.9), 
EuroScore II (8.7 ± 7.5 vs. 7 ± 7.1, p = 0.2), and 
STS score (22.9 ± 25.1 vs. 13.4 ± 10.3, p = 0.9).
Prosthesis implantation was successful in 
99.3% of the younger group (n = 135) and in 96.2% 
of the older patients (n = 25), p = 0.3. Two patients 
died during the procedure (1 from the younger and 
1 from the older group). All patients in the older 
group had femoral access, while in the younger 
group 121 (89%) had femoral, 6 (4.4%) direct-
aorta, 8 (5.9%) transapical route, and 1 patient had 
carotid access.
Table 1. Demography and clinical characteristics of the study group.
Group 1 — younger 
(age < 85; n = 136)
Group 2 — older  
(age ≥ 85; n = 26)
P
Age [years] 76.7 ± 6.4 87.5 ± 2.1
Logistic EuroScore [%] 19.5 ± 15.2 18.5 ± 7.6 NS
EuroScore II [%] 7.4 ± 7.6 5.7 ± 3.1 NS
STS score [%] 13.8 ± 11.8 14.4 ± 9.7 NS
Female 63 (46.3%) 14 (53.8%) NS
Hypertension 91 (66.9%) 15 (57.7%) NS
Diabetes 46 (33.8%) 9 (34.6%) NS
Body mass index [kg/m2] 27.6 ± 4.3 27.7 ± 4.5 NS
Coronary artery disease 80 (58.8%) 14 (53.8%) NS
History of myocardial infarction 45 (33.1%) 9 (34.6%) NS
Atrial fibrillation 46 (33.8%) 8 (30.8%) NS
History of coronary artery bypass grafting 30 (22%) 0 (90%) 0.0047
History of any previous cardiac surgery 34 (25.7%) 0 (0%) 0.0026
History of percutaneous coronary intervention 49 (36%) 10 (38.5%) NS
History of aortic balloon valvuloplasty 7 (5.1%) 0 (0%) NS
Chronic obstructive pulmonary disease or asthma 37 (27.2%) 1 (3.9%) 0.0099
Peripheral arterial disease 32 (23.5%) 3 (11.5%) NS
Carotid artery disease 42 (30.9%) 9 (34.6%) NS
Stroke or transient ischemic attack 14 (10.3%) 3 (11.5%) NS
Frailty (Katz ADL index less than 5) 36 (26.5%) 14 (53.8%) 0.01
Glomerular filtration rate [mL/min] 57.8 ± 19.3 49 ± 15.3 0.045
Creatinine level at baseline [μmol/L] 113.6 ± 38 122.6 ± 42 NS
NT-proBNP level at baseline [pg/mL] 4722.1 ± 5492.5 6080.6 ± 6624.9 NS
Left ventricular ejection fraction at baseline [%] 51.3 ± 11.4 53 ± 9.3 NS
Peak aortic gradient at baseline [mm Hg] 91.8 ± 27.6 93.4 ± 18.8 NS
Mean aortic gradient at baseline [mm Hg] 56.6 ± 18 56.8 ± 12.4 NS
ADL — Activities of Daily Living; NT-proBNP — N-terminal pro-B-type natriuretic peptide; STS — Society of Thoracic Surgeons
www.cardiologyjournal.org 361
Anna Olasinska-Wisniewska et al., Age does not affect outcome of TAVI
In-hospital mortality did not differ significantly 
between the groups. Rates of MI and stroke were 
also comparably low in both groups (Table 2).
Major, life threatening and minor bleeding 
complications, as well as vascular access site com-
plications did not differ between the two groups. 
Similar results were also found in both groups 
(Table 2) regarding the incidence of PVL (p = 0.2), 
pacemaker implantation (p = 0.8) and the length 
of hospitalization (older group 8.8 ± 5 days and 
younger group 9.8 ± 8.6 days, p = 0.4).
One-month follow-up was available for all pa-
tients, 1-year — for a total of 135 (83%) patients 
who completed 12-month follow-up. Five patients 
died during 30 days after the procedure in the 
younger group and two in the older group (p = 0.6). 
One-year mortality was 15.4% in the younger 
and 7.7% in the older group (p = 0.4). Results are 
presented in Table 3 and Figure 1. In the younger 
group, there were 4 in-hospital deaths directly 
related to procedural complications, and 1 death in 
the course of decompensated heart failure. More-
Table 2. Procedural and post-procedural results.
Group 1 — younger 
(age < 85; n = 136)
Group 2 — older  
(age ≥ 85; n = 26)
P
Approach:
Femoral 121 (89%) 26 (100%)
Direct aorta 6 (4.4%) 0 (0%)
Transapical 8 (5.9%) 0 (0%)
Carotid 1 (0.7%) 0 (0%)
CoreValve 93 (68.4%) 16 (61.5%)
CoreValve Evolut R 23 (16.9%) 4 (15.4%)
Symetis 8 (5.9%) 0 (0%)
Lotus 11 (8.1%) 5 (19.2%)
General anesthesia 122 (89.7%) 20 (76.9%) 0.098
Pacemaker implantation 26 (19.1%) 4 (15.4%) NS
Myocardial infarction 1 (0.7%) 0 (0%) NS
Stroke 1 (0.7%) 1 (3.9%) NS
Paravalvular leakage mild 57 (41.9%) 7 (26.9%) NS
Paravalvular leakage moderate 13 (9.6%) 5 (19.2%) NS
Acute kidney injury 52 (38.2%) 11 (42.3%) NS
Creatinine post-procedural max level [μmol/L] 163.6 ± 100.6 167.7 ± 79.7 NS
Bleeding minor 14 (10.3%) 2 (7.7%) NS
Bleeding major 11 (8.1%) 0 (0%) NS
Bleeding life threatening 10 (7.4%) 1 (3.9%) NS
Vascular complications minor 13 (9.6%) 1 (3.9%) NS
Vascular complications  major 10 (7.4%) 1 (3.9%) NS
Hospitalization [days] 9.8 ± 8.6 8.8 ± 5 NS
over, during 1-year observation, 4 cardiac deaths 
and 9 non-cardiac deaths were noted, whereas the 
reason of 3 additional deaths is unknown. In the 
older group, there were 2 in-hospital deaths related 
to procedure complications.
After exclusion of 15 patients with access site 
other than femoral, the minor (p = 1), major (p = 0.35), 
life threatening (p = 1) bleeding complications, 
minor (p = 0.46) and major (p = 0.7) vascular 
complications, as well as in-hospital (p = 0.3) and 
1-year (p = 0.5) death rate were still not significant.
Table 3. All-cause mortality at follow-up.
Group 1  
— younger  
(age < 85)
Group 2  
— older  
(age ≥ 85)
P
In-hospital death 5 (3.7%) 2 (7.7%) 0.3
1-month mortality 6 (4.4%) 2 (7.7%) 0.6
1-year mortality 21 (15.4%) 2 (7.7%) 0.4
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Discussion
Our results suggest that TAVI can be a safe 
procedure even in very elderly patients. Those 
who were 85 or older, compared with the younger 
group, had similar rate of death, MI, stroke, major 
and minor access site, or bleeding complications, 
as well as the rate of pacemaker implantation, PVL, 
AKI and duration of hospitalization.
Until recently, elderly patients were often dis-
qualified from surgical aortic valve replacement as 
the risk of the procedure seemed to exceed expected 
benefits [3]. The age was believed to be an inde-
pendent risk factor of periprocedural mortality and 
morbidity. Therefore, age has been included in every 
risk score, including EuroScore and STS score. For 
example, the EuroScore II predicts higher mortality 
rate in an 85-year-old male without co-morbidities 
undergoing aortic valve replacement (1.36%) than 
in a 60-year-old male with chronic kidney disease 
and severe lung disease with long-term use of 
bronchodilators (1.1%). Patients who are currently 
qualified for surgical aortic valve replacement may 
have numerous co-morbidities included in risk 
scores, as well as some additional, e.g. fragility, 
history of cancer, osteoporosis, porcelain aorta, 
mediastinal radiation, glucosteroid therapy, and 
others. Therefore, risk assessment for aortic valve 
replacement or TAVI, especially in elderly patients, 
may be sometimes problematic.
Our study confirms that TAVI offers a safe 
treatment option even for elderly patients. It is an 
important finding, since currently majority of TAVI 
patients are aged, with approximately 16% of them 
being ≥ 90 years of age in the United States clinical 
practice [4, 5]. It is worth mentioning that TAVI 
registries and trials included patients with mean age 
of 80 [6, 7]. The tendency is quite stable over time. 
The STS/ACC Transcatheter Valve Therapy (TVT) 
registry [8] underlined that TAVI candidates are still 
elderly with several co-morbidities. In their analysis 
of 26, 414 procedures performed in two periods of 
time, (2012–2013 and 2014) the mean age of patients 
was 82 years between 2012 and 2013 and 81 years 
in 2014. Moreover, 91% of patients were ≥ 70 years 
of age, whereas 68% were ≥ 80 years of age.
Studies [4, 9–11] which assessed feasibility 
and safety of TAVI in very old patients, includ-
ing nonagenarians [9], underline good mid-term 
results of the procedure, improvement in physical 
and mental quality of life [4, 9, 10], self-reported 
health [11], and in New York Heart Association 
functional capacity [9]. Elderly individuals expe-
rienced better in-hospital recovery and similar 
short- and mid-term mortality compared to those 
who underwent surgical aortic valve replacement 
[4]. Moreover, TAVI enables early rehabilitation 
and discharge [12, 13].
The mid-term results of elderly patients were 
good in our study. Abramowitz et al. [9] and Havakuk 
et al. [14] noted higher rate of minor vascular com-
plications and Yamamoto et al. [15] higher rate of 
major vascular complication in elderly subjects. 
These observations might be attributed to the 
increased rate of transfemoral vs. alternative ac-
cess sites and higher rate of calcification of femoral 
arteries in an advanced age. All elderly patients 
in our study had transfemoral access, but neither 
major nor minor vascular complication rates were 
higher when compared to the younger group. Similar 
to other reports [9], our younger group presented 
higher percentage of COPD and history of cardiac 
surgery, which may be explained as qualification of 
more severely ill patients to TAVI.
Alsara et al. [4] reported that 30-day and 
1-year mortality rates were statistically higher in 
older compared with younger patients undergoing 
TAVI, but we did not confirm this observation in 
our study.
Limitations of the study
The main limitations of our study are the 
heterogeneity and small number of patients in the 
Figure 1. Kaplan-Meier 12-month survival curves of the 
study group.
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study group. However, such analysis reflects typi-
cal, real world population of patients with severe 
aortic stenosis treated currently with TAVI in most 
of institutions.
Conclusions
Transcatheter aortic valve implantation in 
patients aged 85 or older is still a relatively safe 
procedure and age itself should not be a discrimina-
tory factor in TAVI qualification.
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